We learned earlier this week that Jacques Chambers passed away on Jan. 11. Even if that name doesn't ring a bell for you, it's likely that if you're part of the HIV community, you've been touched in some way by his efforts.
We take a quick, visually engaging look at some of the most significant developments of the year in HIV/AIDS, as seen through the eyes of one of the world's foremost HIV doctors.
Stribild, a once-daily, single-pill regimen, and Tivicay, a recently approved integrase inhibitor, are now officially on the list of "preferred" HIV medications in official U.S. HIV treatment guidelines.
Mental health really matters in HIV. We got a hugely important reminder of that this month in the form of new research regarding suicide and Sustiva (also known as Stocrin or efavirenz; part of the fixed-dose combination pill Atripla).
The research ...
"It's difficult to express how grateful all of us here are to the people who have opened their lives to us -- and to all of you -- by letting us into their homes and sharing with us their highs and lows."
"We have entered a cure renaissance in the HIV community. 'Cure' has stopped being a word we only utter sarcastically under our breath."
We've seen new signs that it may be possible -- really, truly possible -- to defang HIV in a person who's living with the virus. But for this to work, the person may need to start taking HIV meds very quickly after infection.